Experience
A selection from 2023–2024. Names are anonymized; the work is not. Filter by industry or year.
Showing 24 matters
Acted for the seller on the carve-out of a global industrial subsidiary, coordinating antitrust filings in five jurisdictions and negotiating a complex transition services agreement.
Closed in 11 months with unconditional clearance in all five jurisdictions.
Acted for the special committee in the going-private transaction of a NYSE-listed industrial consolidator, navigating concurrent securities class action litigation.
Closed at $52 per share, a 38% premium to unaffected price.
Structured a 50/50 joint venture between two pharmaceutical majors to develop and commercialize a late-stage oncology pipeline.
JV agreement signed in 7 months; first drug approval expected in 2026.
Acted for a U.S. pharma acquirer on the acquisition of an Asia-based target, with concurrent IP and tax structuring across seven jurisdictions.
Closed with full step-up in basis and IP ownership consolidated in holding company.
Defended a technology company and its officers in a securities class action alleging misstatements regarding product launches.
Complete defense verdict after a five-week jury trial in the Southern District of New York.
Acted for the debtor in the Chapter 11 case of an industrial manufacturer, negotiating a DIP facility and a plan of reorganization that returned value to unsecured creditors.
Plan confirmed in 14 months; unsecured creditor recovery of 92 cents on the dollar.
Obtained Chapter 15 recognition of a Singaporean scheme of arrangement for a financial services group with operations across Asia.
Recognition granted in 6 weeks; global restructuring concluded in 18 months.
Acted for the underwriters on the HKEX IPO of a mainland technology company, with a concurrent Reg S placement.
Oversubscribed 12x; listing raised HK$9.3 billion.
Acted for the issuer on a dual-primary listing on the HKEX and NYSE, navigating conflicting disclosure standards and concurrent SEC review.
Listed with $2.1B raised across both exchanges.
Acted for the issuer on the LSE IPO of a European logistics REIT, the largest REIT IPO in London that year.
Oversubscribed 4x; listed at the top of the range.
Resolved a multi-year transfer pricing examination by the IRS Large Business & International division for a multinational technology company.
No adjustments; advance pricing agreement signed covering the next five years.
Structured the cross-border reorganization of an industrial group to achieve a full step-up in basis across nine jurisdictions.
Implemented with no current tax cost; expected annual savings of $40M.
Defended a registered swap dealer in a CFTC enforcement investigation concerning trade reporting and supervision.
Matter closed with a no-action letter; no civil penalty.
Coordinated merger notifications before the European Commission, CMA, FTC, DOJ, and SAMR for an industrial consolidation.
Unconditional clearance in all five jurisdictions; Phase II avoided in EU and UK.
Defended a global manufacturer in a European Commission cartel investigation into automotive components.
Zero fine for the client; immunity under the EC Leniency Programme.
Defended a technology platform in a European Commission investigation into alleged abuse of dominance.
Investigation closed with commitments; no finding of infringement.
Defended a Section 337 investigation before the ITC alleging patent infringement in imported consumer electronics.
No violation found; no exclusion order issued.
Acted for the acquirer on the purchase of a global patent portfolio spanning 4,200 assets across 14 jurisdictions.
Closed in 4 months; full chain of title confirmed post-close.
Defended a pharmaceutical company in patent litigation before the Federal Circuit, on appeal from a District Court claim construction.
Federal Circuit reversed; claims construed in client's favor.
Defended an industrial manufacturer in an FLSA collective action alleging off-the-clock work across 28 facilities.
Decertified the collective; individual settlements at a fraction of exposure.
Defended a financial services firm in an EEOC pattern-or-practice investigation into promotion practices.
Investigation closed with a letter of determination; no cause finding.
Coordinated a reduction-in-force affecting 2,800 employees across 22 countries, with concurrent securities disclosure and works council consultation.
Implemented on schedule; no litigation filed.
Acted for a sovereign wealth fund on the acquisition of a Central London office portfolio comprising 11 assets.
Closed in 6 months; debt arranged concurrently with acquisition.
Acted for an institutional investor on the disposal of a European logistics platform spanning six countries.
Closed at a 12% premium to the book value; simultaneous closing across 6 jurisdictions.
No matters match your filters. .
Timeline
Each row is a practice. Each bar is a year. The bar length is the number of matters.
| Practice | 2023 | 2024 | Total |
|---|---|---|---|
| Mergers & Acquisitions | 2 | 2 | 4 |
| Litigation | 0 | 1 | 1 |
| Capital Markets | 2 | 1 | 3 |
| Tax | 1 | 1 | 2 |
| Antitrust & Competition | 1 | 1 | 2 |
| Intellectual Property | 1 | 2 | 3 |
| Labor & Employment | 1 | 2 | 3 |
| Real Estate | 1 | 1 | 2 |
| Restructuring & Insolvency | 1 | 1 | 2 |
| Regulatory & Government Affairs | 1 | 1 | 2 |